CTS Corporation reported a 5% revenue increase to $150 million in Q3 2026, driven by a 7% rise in diversified end markets, which now make up 60% of sales. The company achieved record profitability with a 42.2% gross margin and adjusted EBITDA margin of 24.7%, alongside an adjusted EPS of $0.77. Growth in diversified markets offset modest transportation sales, improving earnings quality. CTS also announced the acquisition of Millar, enhancing its medical market presence and expanding its advanced pressure sensing technology portfolio, signaling strategic growth plans.
CTS Corporation's Q3 2026 earnings call highlights a 5% revenue increase to $150 million and record profitability with a 42.2% gross margin. For readers following Industrials-sector US stocks, here is Pluang's market snapshot as of Oct 28, 2026 03:12 WIB: out of 135 priced stocks, 84 rose and 51 fell. Notable movers include TE (T1 Energy Inc.) with a 16.51% gain and 79% buy activity, XYL (Xylem, Inc.) down 13.71% but with 97% buy activity, and EOSE (Eos Energy Enterprises Inc) up 13.58% with a balanced buy/sell order split.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
